The cleavage of C5 into fragments C5a and C5b is a critical event during the complement cascade, as C5a is a potent pro-inflammatory anaphylatoxin capable of inducing cell migration, adhesion and ...

A study published in the Journal of Immunology shows for the first time that inhibition of the receptor for the pro-inflammatory complement factor C5a (C5aR) reduces the neuropathology and rescues ...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR.

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the ...